NCT06015152View on ClinicalTrials.gov

Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis

NACompletedINTERVENTIONAL

Enrollment

90

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

December 1, 2022

Study Completion Date

February 1, 2023

Conditions

Scalp Psoriasis

Interventions

DRUG

Tazarotene 0.045% Topical Application Lotion [ARAZLO]

\[ARAZLO\]

Trial Locations (1)

Unknown

JPMC, Karachi

All Listed Sponsors

lead

Jinnah Postgraduate Medical Centre

OTHER_GOV